TC

TCG Crossover Management, LLC

Diversified strategySector-focusedContrarian

Total reported value

$3.5B

Reporting period: 2026-03-31 · Number of holdings: 49

TCG Crossover Management, LLC disclosed 49 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $3.5B and a quarterly turnover rate of 57.6%.

Personality snowflake

Concentration
27.57
Portfolio Stability
57.57
Momentum/Contrarian
0
Sector conviction
100
Diversification
98
Sizing Uniformity
84.42

Recent moves

  • Trim ABVX

    -8.9%　-$237.4M

  • Add MIRM

    +1611.6%　$93.2M

  • Add TNGX

    -17.5%　$107.2M

  • Add CGON

    0.0%　$96.0M

  • Trim GPCR

    -84.8%　-$57.3M

  • Trim OCUL

    -71.3%　-$55.7M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1ABVXAbivax Sa-adrStock-Other20.65%-11.09%-8.87%
2CGONCg Oncology INCStock-Other7.11%+2.07%—
3TNGXTango Therapeutics INCStock-Other6.30%+2.56%-17.48%
4COGTCogent Biosciences INCStock-Other5.45%-1.45%-15.70%
5260Centessa Pharmaceuticals-adrStock-Other4.87%+1.32%—
6DNTHDianthus Therapeutics INCStock-Other4.03%+1.74%—
7TYRATyra Biosciences INCStock-Other3.56%+1.04%+12.11%
8IMVTImmunovant INCStock-Other3.17%+1.77%+168.40%
9BCRXBiocryst Pharmaceuticals INCStock-Other3.00%+3.00%NEW
10MIRMMirum Pharmaceuticals INCStock-Other2.81%+2.65%+1611.63%
11VORVor Biopharma INCStock-Other2.76%+2.76%NEW
12SYRESpyre Therapeutics INCStock-Other2.74%+0.68%—
13AMLXAmylyx Pharmaceuticals INCStock-Other2.48%-0.02%—
14IRONDisc Medicine INCStock-Other2.45%+2.45%NEW
15DYNDyne Therapeutics INCStock-Other2.39%-0.60%—
16GLUEMonte Rosa Therapeutics INCStock-Other2.18%-0.22%—
17SVRASavara INCStock-Other1.93%-0.54%—
18RVMDRevolution Medicines INCStock-Healthcare1.60%+0.45%+32.08%
19KODKodiak Sciences INCStock-Other1.58%+0.24%—
20LBRXLb Pharmaceuticals INCStock-Other1.30%+0.01%+5.41%
21SRZNSurrozen INCStock-Other1.23%+1.23%NEW
22✓ Adc Therapeutics SAStock-Other1.22%-0.11%—
23RLAYRelay Therapeutics INCStock-Other1.22%+0.32%+32.71%
24FULCFulcrum Therapeutics INCStock-Other1.15%-0.81%—
25BHVNBiohaven Ltd.Stock-Other1.12%-0.61%—
26IPSCCentury Therapeutics INCStock-Other1.12%+1.12%NEW
27TECXTectonic Therapeutic INCStock-Other1.07%+1.07%NEW
28CATXPerspective Therapeutics INCStock-Other0.94%+0.94%NEW
29XNCRXencor INCStock-Other0.85%-0.39%—
30TRDAEntrada Therapeutics INCStock-Other0.83%+0.12%+9.53%
31ALXOAlx Oncology Holdings INCStock-Other0.75%+0.75%NEW
32ARVNArvinas INCStock-Other0.72%-0.33%-10.46%
33JANXJanux Therapeutics INCStock-Other0.71%——
34AGMBAgomab Therapeutics NVStock-Other0.62%+0.62%NEW
35ALECAlector INCStock-Other0.62%+0.10%—
36MBXMbx Biosciences INCStock-Other0.56%——
37SLNSilence Therapeutics Plc-adrStock-Other0.46%-0.15%—
38LQDALiquidia CORPStock-Other0.44%-1.51%-76.43%
39OCULOcular Therapeutix INCStock-Other0.40%-1.91%-71.29%
40AVTXAvalo Therapeutics INCStock-Other0.32%+0.03%+52.87%
41URGNUroGen Pharma Ltd.Stock-Other0.21%-0.35%-43.49%
42MNPRMonopar Therapeutics INCStock-Other0.21%-0.10%-6.91%
43CNTXContext Therapeutics INCStock-Other0.20%+0.20%NEW
44GPCRStructure Therapeutics INCStock-Other0.19%-1.93%-84.75%
45CGEMCullinan Therapeutics INCStock-Other0.17%+0.17%NEW
46KRROKorro Bio INCStock-Other0.13%+0.02%—
47LONALeonabio INCStock-Other0.13%——
48UPBUpstream Bio INCStock-Other0.05%-0.62%-75.66%
49VTGNVistagen Therapeutics INCStock-Other0.04%——

Holding changes this quarter

TCG Crossover Management, LLC's most significant position changes for 2026-03-31: New buy: Biocryst Pharmaceuticals INC (BCRX); New buy: Vor Biopharma INC (VOR); Sold out: Rapt Therapeutics INC (RAPT); New buy: Disc Medicine INC (IRON); Sold out: Eyepoint INC (EYPT).

Position changes disclosed by TCG Crossover Management, LLC for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1MIRMMirum Pharmaceuticals INC+2.7%+1611.63%Add
2TNGXTango Therapeutics INC+2.6%-17.48%Trim
3CGONCg Oncology INC+2.1%—Unchanged
4IMVTImmunovant INC+1.8%+168.40%Add
5DNTHDianthus Therapeutics INC+1.7%—Unchanged
6260Centessa Pharmaceuticals-adr+1.3%—Unchanged
7TYRATyra Biosciences INC+1%+12.11%Add
8SYRESpyre Therapeutics INC+0.7%—Unchanged
9RVMDRevolution Medicines INC+0.5%+32.08%Add
10RLAYRelay Therapeutics INC+0.3%+32.71%Add
11KODKodiak Sciences INC+0.2%—Unchanged
12TRDAEntrada Therapeutics INC+0.1%+9.53%Add
13ALECAlector INC+0.1%—Unchanged
14AVTXAvalo Therapeutics INC0%+52.87%Add
15KRROKorro Bio INC0%—Unchanged
16LBRXLb Pharmaceuticals INC0%+5.41%Add
17AMLXAmylyx Pharmaceuticals INC0%—Unchanged
18MNPRMonopar Therapeutics INC-0.1%-6.91%Trim
19✓ Adc Therapeutics SA-0.1%—Unchanged
20SLNSilence Therapeutics Plc-adr-0.2%—Unchanged
21GLUEMonte Rosa Therapeutics INC-0.2%—Unchanged
22ARVNArvinas INC-0.3%-10.46%Trim
23URGNUroGen Pharma Ltd.-0.4%-43.49%Trim
24XNCRXencor INC-0.4%—Unchanged
25SVRASavara INC-0.5%—Unchanged
26DYNDyne Therapeutics INC-0.6%—Unchanged
27BHVNBiohaven Ltd.-0.6%—Unchanged
28UPBUpstream Bio INC-0.6%-75.66%Trim
29FULCFulcrum Therapeutics INC-0.8%—Unchanged
30COGTCogent Biosciences INC-1.5%-15.70%Trim
31LQDALiquidia CORP-1.5%-76.43%Trim
32OCULOcular Therapeutix INC-1.9%-71.29%Trim
33GPCRStructure Therapeutics INC-1.9%-84.75%Trim
34ABVXAbivax Sa-adr-11.1%-8.87%Trim
35BCRXBiocryst Pharmaceuticals INC—NEWNew buy
36VORVor Biopharma INC—NEWNew buy
37RAPTRapt Therapeutics INC—EXITSold out
38IRONDisc Medicine INC—NEWNew buy
39EYPTEyepoint INC—EXITSold out
40SRZNSurrozen INC—NEWNew buy
41IPSCCentury Therapeutics INC—NEWNew buy
42TECXTectonic Therapeutic INC—NEWNew buy
43CATXPerspective Therapeutics INC—NEWNew buy
44AGIOAgios Pharmaceuticals INC—EXITSold out
45ALXOAlx Oncology Holdings INC—NEWNew buy
46AGMBAgomab Therapeutics NV—NEWNew buy
47MAZEMaze Therapeutics INC—EXITSold out
48CNTXContext Therapeutics INC—NEWNew buy
49CGEMCullinan Therapeutics INC—NEWNew buy
50VTYXUSDVentyx Biosciences INC—EXITSold out

FAQ

What is TCG Crossover Management, LLC and what type of investor is it?
TCG Crossover Management, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $3.5B, spread across 49 disclosed positions.
What are TCG Crossover Management, LLC's largest equity positions?
Based on the latest 13F filing, TCG Crossover Management, LLC's top holdings by market value are: 1. Abivax Sa-adr (ABVX) — $721.7M (20.6%) 2. Cg Oncology INC (CGON) — $248.4M (7.1%) 3. Tango Therapeutics INC (TNGX) — $220.3M (6.3%) 4. Cogent Biosciences INC (COGT) — $190.4M (5.5%) 5. Centessa Pharmaceuticals-adr (260) — $170.3M (4.9%)
What changes did TCG Crossover Management, LLC make in its most recent portfolio filing?
In the latest reported quarter, TCG Crossover Management, LLC made 34 notable position adjustments: 11 new positions were initiated, 8 existing holdings were added to, 10 positions were partially reduced, and 5 were completely exited. The largest of these moves: New buy: Biocryst Pharmaceuticals INC (BCRX); New buy: Vor Biopharma INC (VOR); Sold out: Rapt Therapeutics INC (RAPT); New buy: Disc Medicine INC (IRON); Sold out: Eyepoint INC (EYPT)
What sectors does TCG Crossover Management, LLC focus on?
TCG Crossover Management, LLC is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%